275 related articles for article (PubMed ID: 22425095)
1. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
Rini BI; Garcia J; Elson P; Wood L; Shah S; Stephenson A; Salem M; Gong M; Fergany A; Rabets J; Kaouk J; Krishnamurthi V; Klein E; Dreicer R; Campbell S
J Urol; 2012 May; 187(5):1548-54. PubMed ID: 22425095
[TBL] [Abstract][Full Text] [Related]
2. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
3. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
4. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
5. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
Gorin MA; Ekwenna O; Soloway MS; Ciancio G
Urology; 2012 Feb; 79(2):e11. PubMed ID: 21676439
[TBL] [Abstract][Full Text] [Related]
6. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant therapy for renal cancer].
Thibault F; Rixe O; Meric JB; Renard-Penna R; Boostan H; Mozer P; Comperat E; Richard F; Bitker MO
Prog Urol; 2008 Apr; 18(4):256-8. PubMed ID: 18501308
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Bex A; de Gast G; Haanen JB; Boven E
Clin Cancer Res; 2008 Apr; 14(8):2431-6. PubMed ID: 18413834
[TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.
Hellenthal NJ; Underwood W; Penetrante R; Litwin A; Zhang S; Wilding GE; Teh BT; Kim HL
J Urol; 2010 Sep; 184(3):859-64. PubMed ID: 20643461
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH
BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
[TBL] [Abstract][Full Text] [Related]
14. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
[TBL] [Abstract][Full Text] [Related]
15. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
16. [NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].
Stakhovskiy EO; Voylenko OA; Stakhovskiy OE; Vitruk YV; Vukalovych PS; Kononenko OA
Klin Khir; 2015 Dec; (12):41-3. PubMed ID: 27025031
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
19. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
